Patrick Boyle

Patrick Boyle is the Head of Codebase at Ginkgo Bioworks, a Boston-based synthetic biology company that makes and sells engineered organisms. The Codebase team leads Ginkgo's customer facing programs and develops the company's "Codebase" portfolio of reusable biological assets. Ginkgo's Codebase includes thousands of novel strains, enzymes, genetic parts, and diverse genetic repositories, including millions of engineered DNA sequences.

During the COVID-19 pandemic, Patrick has been responsible for coordinating Ginkgo's COVID response programs in the area of therapeutics and vaccines. Much of this work has focused on optimizing the production of raw materials for nucleic acid vaccines, including Moderna's mRNA-1273 COVID-19 vaccine.

Patrick was a 2014 fellow in the Johns Hopkins University Center for Health Security's Emerging Leaders in Biosecurity Program, and currently serves on the Board of Life Sciences for the National Academies of Sciences, Engineering, and Medicine.

Prior to Ginkgo, Patrick received his PhD from Harvard Medical School in 2012, developing synthetic biology applications in bacteria, yeast, and plants in the lab of Dr. Pamela Silver. He received an SB in biology from the Massachusetts Institute of Technology in 2006.